Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial
Cancer Immunology, Immunotherapy · Published 2026-07-06 · DOI 10.1007/s00262-026-04481-1 · PMID: 42406083
Free full text
Authors (7)
Liangjie Sun, Peiwen Ma, Zhenwei Miao, Na Su, Jinduo Bian, Shuhang Wang, Ning Li
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Sun, L., Ma, P., Miao, Z., et al. (2026). Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04481-1
Related articles
- NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study · Cancer Immunology, Immunotherapy · 2025 · Cites or is cited by this article · Same journal
- HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis · Cancer Immunology, Immunotherapy · 2026 · Same journal